GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Price-to-Free-Cash-Flow

GlobeStar Therapeutics (GlobeStar Therapeutics) Price-to-Free-Cash-Flow : N/A (As of May. 26, 2024)


View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-05-26), GlobeStar Therapeutics's share price is $0.0007. GlobeStar Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Hence, GlobeStar Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for GlobeStar Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, GlobeStar Therapeutics's highest Price-to-Free-Cash-Flow Ratio was 250.00. The lowest was 0.00. And the median was 50.00.

GSTC's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.69
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

GlobeStar Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.00.

During the past 13 years, GlobeStar Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 92.60% per year. The lowest was 12.60% per year. And the median was 57.50% per year.


GlobeStar Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for GlobeStar Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeStar Therapeutics Price-to-Free-Cash-Flow Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GlobeStar Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlobeStar Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, GlobeStar Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlobeStar Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeStar Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where GlobeStar Therapeutics's Price-to-Free-Cash-Flow falls into.



GlobeStar Therapeutics Price-to-Free-Cash-Flow Calculation

GlobeStar Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.0007/0
=N/A

GlobeStar Therapeutics's Share Price of today is $0.0007.
GlobeStar Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

GlobeStar Therapeutics  (OTCPK:GSTC) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


GlobeStar Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of GlobeStar Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeStar Therapeutics (GlobeStar Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.
Executives
James C Katzaroff director, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
William J Farley director 468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski officer: CFO 145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship director, officer: CEO, Pres., Secr., Treas. 14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood 10 percent owner 5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau director 770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer director 1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz director, officer: Interim CEO & Chairman 495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550